Verastem Inks Material Agreement, New Financial Obligation
Ticker: VSTM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, debt, financial-obligation
TL;DR
**Verastem just took on a new financial obligation, watch for details on its impact.**
AI Summary
Verastem, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 4, 2024, concerning the entry into a material definitive agreement and the creation of a direct financial obligation. This filing indicates a significant new financial commitment for Verastem, Inc., which could impact its balance sheet and future financial flexibility. Investors should be aware that new financial obligations can affect a company's cash flow and profitability, potentially influencing the stock's valuation.
Why It Matters
This filing signals a new financial commitment for Verastem, Inc., which could affect its liquidity and future earnings, directly impacting shareholders.
Risk Assessment
Risk Level: medium — The filing indicates a new financial obligation without specifying the amount or terms, creating uncertainty about its potential impact on the company's financial health.
Analyst Insight
Investors should monitor Verastem, Inc.'s subsequent filings or press releases for specific details regarding the material definitive agreement and the direct financial obligation, as these will clarify the actual impact on the company's financial health and future prospects.
Key Players & Entities
- Verastem, Inc. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — date of the earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
- 001-35403 (other) — Commission File Number
- VSTM (other) — Trading Symbol on The Nasdaq Capital Market
FAQ
What was the specific nature of the 'Material Definitive Agreement' Verastem, Inc. entered into on January 4, 2024?
The filing indicates the entry into a 'Material Definitive Agreement' but does not provide specific details about its nature, terms, or the parties involved. Further information would be needed to understand the specifics of this agreement.
What is the exact amount and terms of the 'Direct Financial Obligation' created by Verastem, Inc. as reported on January 4, 2024?
The 8-K filing states the 'Creation of a Direct Financial Obligation' but does not disclose the specific dollar amount, interest rates, repayment schedule, or other key terms of this obligation. This information is not available in the provided text.
Why did Verastem, Inc. choose to file this information under Item 1.01 and Item 2.03 of Form 8-K?
Verastem, Inc. filed under Item 1.01 because it entered into a 'Material Definitive Agreement' and under Item 2.03 because it created a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant'. These items are standard for reporting such significant corporate events.
What is Verastem, Inc.'s primary business according to the filing?
According to the filing, Verastem, Inc.'s Standard Industrial Classification (SIC) is 'PHARMACEUTICAL PREPARATIONS [2834]', indicating its primary business is in the pharmaceutical industry.
On which exchange is Verastem, Inc.'s common stock traded, and what is its par value?
Verastem, Inc.'s common stock, with a par value of $0.0001 per share, is traded on The Nasdaq Capital Market under the trading symbol VSTM.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-08 16:02:35
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm242257d1_8k.htm (8-K) — 24KB
- tm242257d1_ex10-1.htm (EX-10.1) — 34KB
- 0001104659-24-002227.txt ( ) — 234KB
- vstm-20240104.xsd (EX-101.SCH) — 3KB
- vstm-20240104_lab.xml (EX-101.LAB) — 33KB
- vstm-20240104_pre.xml (EX-101.PRE) — 22KB
- tm242257d1_8k_htm.xml (XML) — 3KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement On January 4, 2024, Verastem, Inc. (the "Company") amended its Loan and Security Agreement, dated March 25, 2022 (as amended, the "Loan Agreement") with Oxford Finance LLC, as collateral agent and a lender, and the other lenders identified on the signature pages thereto. The amendment extends the outside date for the period during which the Company may draw the Term C Loan (as defined in the Loan Agreement) from March 31, 2024, to March 31, 2025. A copy of the amendment is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The forgoing summary of the amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the amendment and the Loan Agreement.
03. Creation of a Direct Financial
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 First Amendment to Loan and Security Agreement, dated as of January 4, 2024, among Verastem, Inc., as borrower, Oxford Finance LLC, as collateral agent and a lender, and the other lenders party thereto. 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: January 8, 2024 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer